RBMS1 and cancer: Current studies have shown that YC-1 has a wide spectrum of pharmacological activities, including anti-platelet [22–24], anti-inflammatory [25–29], anti-angiogenesis [30], neuro-protective [31–33], anti-hepatic fibrosis [34] and anti-cancer properties [20, 33, 35–56].